SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. engages in the design, manufacture, and launch of rockets and spacecrafts. It provides satellite communication services. The company was founded by Elon Reeve Musk on March 14, 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently trending as investors debate the massive valuation of its record-breaking IPO, with the community split between long-term bullish optimism for space infrastructure and bearish warnings regarding overvaluation and potential liquidity risks. While some retail traders are aggressively accumulating shares to hold for the future, others are actively scouting for entry points below IPO levels, waiting for the initial hype and volatility to settle.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is seeing high volatility and intense community speculation following a recent report that the company is exploring a potential sale to a major media entity. Investors are actively debating the viability of a buyout versus a standalone growth strategy, with many weighing the companys platform dominance and recent profitability against ongoing market skepticism and competitive pressures.

Entrepreneurshares Series Trust - ERShares Private-Public Crossover ETF

The ERShares Private-Public Crossover ETF (XOVR) is trending as investors debate its structure and valuation in relation to its significant exposure to SpaceX. While some community members are frustrated by the fund's recent price stagnation despite SpaceX's growth, others view it as an accessible, liquid entry point for pre-IPO space exposure compared to more volatile alternatives.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as investors weigh potential antitrust hurdles, including reports of state-level lawsuits, against the company's efforts to finalize its major acquisition of Warner Bros. Discovery. While some community members remain focused on regulatory timelines and the strategic integration of content, others are actively debating the potential impact on share price and the long-term viability of the combined entity.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing heavy volatility and downward pressure as capital rotates into the high-profile SpaceX IPO, creating a liquidity vacuum across the space sector. Despite the selling, community members remain focused on the upcoming launch of new satellites as a critical catalyst to validate long-term growth and spark a recovery.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is experiencing significant volatility and downward pressure as investors rotate out of the fund to pursue direct exposure to the upcoming SpaceX IPO, which has triggered widespread selling despite the fund's heavy concentration in high-growth private tech assets. The community remains deeply divided, with some investors aggressively adding to positions on the belief that current market prices trade at a steep discount to the fund's true net asset value, while others are frustrated by management's dilution through share offerings and a lack of communication regarding the fund's underlying valuation.

Tidal Trust II - Defiance Daily Target 2X Short ASTS ETF

ASTN is seeing significant volatility as traders leverage the ETF to play against the momentum of ASTS, which many investors view as a highly volatile meme stock. The community remains deeply divided, with bearish traders utilizing the 2X inverse ETF to bet on a correction while long-term bulls continue to debate the stock's valuation and potential for further gains.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing strong community interest as positive clinical data for its subcutaneous Briumvi treatment fuels expectations for a potential buyout. Investors are closely monitoring management's commentary and institutional positioning, with many hopeful that upcoming industry conferences will further validate the stock's long-term growth trajectory.

ROAM Token

The ROAM community is generating significant buzz around the intersection of its decentralized connectivity network, eSIM travel utility, and a new AI-driven creative challenge. Supporters are highlighting the project's real-world infrastructure growth and its transition into an AI-ready ecosystem, while debate continues regarding its marketing strategy and long-term token utility.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF is capturing attention as investors rotate toward quality-tilted, dividend-growth strategies to balance portfolio volatility. The community remains focused on long-term accumulation, with ongoing discussions emphasizing the fund's role as a core defensive anchor that provides income stability through market cycles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines

Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.

Novartis Reports Positive Data for Neuromuscular Disorder Drug 

NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying treatment for FSHD.

Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B

Incyte will acquire Vega Therapeutics for up to $2B, adding late-stage VWD candidate VGA039 and expanding its hematology growth prospects.

What's Driving Amneal's 2026 Growth Outlook?

AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth from complex generics, injectables, and specialty brands.

BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag

Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.

FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy

VRTX moves closer to a potential nephrology launch as the FDA accepts its BLA for povetacicept in adults with IgAN, with a decision due in November 2026.

"Closing The Nuclear Fuel Cycle" - Newcleo's $780M War Chest And Oklo Partnership Fuel $2.4B SPAC Debut

AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue?

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cancer Stocks That Are Advancing the Future of Oncology Care

Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.

Ralph Baric And UNC's Biodefense Contract Racket Exposed

Ralph Baric And UNC's Biodefense Contract Racket Exposed Authored by Paul D. Thacker via The DisInformation Chronicle, DLA Piper wants to get you, I was told, from a source in DC over the weekend...

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Current Price	$153.07
Prev Close	$153.92
Open	$153.93
Dividend Yield	2.23%
50-Day Moving Average	$149.22
Beta	0.29
Avg. Volume	1.26M
PE Ratio	21.80

52-Week High	$170.46
52-Week Low	$112.34
Market Capitalization	$281.76B
EPS (Annual)	$7.25
Price to Book	7.63
Revenue Per Employee	$728,224.22

NVSNovartis AG

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVS News